FIELD: pharmacology.
SUBSTANCE: group of inventions relates to a solid form of indinavir sulfate, which is a capsule containing 67-79 wt % of indinavir sulfate, 10-20 wt % of lactose monohydrate, 7.7-15 wt % of Prosolv, 0.5-3 wt % of sodium croscarmellose (primellose) 0.5-1 wt % of stearic acid and/or its salt; and a method for its production, according to which indinavir sulfate, lactose monohydrate, croscarmellose sodium and Prosolv are mixed, dusted with stearic acid and/or its salt, encapsulated with simultaneous capsules dedusting and polishing.
EFFECT: prompt active agent release and reduced timing of therapeutic effect.
5 cl, 3 tbl
